Kemocarb

Initial treatment of advanced ovarian carcinoma in established combination w/ other approved chemotherapeutic agents. Palliative treatment of recurrent ovarian carcinoma after prior chemotherapy, including previous treatment w/ cisplatin.

IV Administer by infusion lasting ≥15 min. Previously untreated patient w/ advanced ovarian carcinoma 300 mg/m² carboplatin & 600 mg/m² cyclophosphamide on day 1 every 4 wk for 6 cycles. Patient w/ recurrent ovarian carcinoma 360 mg/m² carboplatin on day 1 every 4 wk. Patient w/ CrCl 41-59 mL/min 250 mg/m² carboplatin on day 1, 16-40 mL/min 200 mg/m² carboplatin on day 1.

Patients w/ history of severe allergic reactions to cisplatin or other platinum-containing compd. Patients w/ severe bone marrow depression or significant bleeding.

Nephrotoxic, carcinogenic, mutagenic, embryotoxic & teratogenic potential. Bone marrow suppression (leukopenia, neutropenia, & thrombocytopenia) is dose-dependent & is also the dose-limiting toxicity. Frequently monitor peripheral blood counts during treatment &, when appropriate, until recovery is achieved. Reports of clinically significant hearing loss in ped patients when administered at higher than recommended doses in combination w/ other ototoxic agents. Can induce emesis, which can be more severe in patients previously receiving emetogenic therapy. Increased incidence of peripheral neurotoxicity in patients >65 yr & in patients previously treated w/ cisplatin. Reports of vision loss after use of doses higher than recommended. Increased risk of allergic reactions including anaphylaxis in patients previously exposed to platinum therapy. Severe LFT abnormalities w/ high doses (>4 times the recommended dose). Carefully manage use in combination w/ other bone marrow suppressing therapies to minimize additive effects. Do not use Al-containing needles or IV sets for prep or administration. Caution when concomitantly treated w/ aminoglycosides. Increased risk of severe bone marrow suppression in patients w/ CrCl <60 mL/min. Limited data available for patients w/ severe renal impairment (CrCl <15 mL/min). May cause fetal harm when administered to a pregnant woman. Women of childbearing potential should avoid becoming pregnant during treatment. Discontinue breastfeeding during treatment. Safety & effectiveness in ped patients have not been established.

Thrombocytopenia, neutropenia, leukopenia, anemia, infections, bleeding, transfusions; nausea, vomiting, other GI side effects (pain, diarrhea, constipation); peripheral neuropathies, ototoxicity, other sensory side effects (visual disturbances, change in taste), central neurotoxicity; elevated serum creatinine & blood urea; elevated bilirubin, SGOT, alkaline phosphatase; electrolyte loss (Na, K, Ca, Mg); pain, asthenia, alopecia, mucositis, hypersensitivity, inj site reactions; CV, resp, genitourinary side effects.

Potentiated renal effects of nephrotoxic compd. Increased renal &/or audiologic toxicity w/ aminoglycosides. Precipitate formation & loss of potency w/ Al.

Cytotoxic Chemotherapy

L01XA02 - carboplatin ; Belongs to the class of platinum-containing antineoplastic agents. Used in the treatment of cancer.

P₁S₁S₃